Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Titans Of Pharma 2024

How do big pharma CEO compensation packages stack up against company performance? 

Read More

Featured Stories


M&A Activity During Q2 Declined In Volume And Valuation

Following a pair of $10bn+ deals in Q4 2023 and a $16.5bn takeout in Q1, the second quarter saw no acquisition priced as high as $5bn, Evaluate notes. Aggregate deal volume and values dropped from Q1.

Evaluate Data M & A Business Strategies

How The IRA Factored Into Akebia’s Price For Vafseo

Akebia said it had set the price for Vafseo at about $15,500 per year, meant to reflect its potential value in dialysis as well as eventually in non-dialysis patients.

Market Access Pricing Strategies Renal

The Prospects For Earlier-Stage Antibody-Drug Conjugates

Around 25 ADCs are in active Phase I/II trials, with a range of mechanistic approaches.

Clinical Trials Commercial Companies

Asia Spotlight

India Pharma Chiefs On Supply Chain Learnings From Auto Sector, New ‘PAGE’ On Skilling

Leaders from India’s top drug makers discuss efforts to operationalize a world-class skilling institute, backed by tie-ups with organizations like the PDA, ISPE and also taking a leaf out of the automobile industry’s book to build supply chain resilience. They also exuded confidence on moving up the innovation value chain.


India Commercial

More coverage from Scrip's team in Asia

Scrip Podcast

Insights and perspectives on commercial, R&D, deal-making and business strategy developments.

MORE PODCASTS

 

Scrip Originals

Pipeline Watch: 11 Approvals And Two Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Approvals

Executives On The Move: Three New CEOs Among This Week's Changes

Recent moves in the industry include C-suite shuffle at Armis Biopharma, plus Voyager Therapeutics acquires chief financial officer from Vor Biopharma.

Leadership Executive Changes

Stock Watch: Biotechs Sell The Family Silver

When loss-making biotech companies mix debt with sluggish sales, difficult options like restructuring and asset sales remain.

Stock Watch M & A

Pipeline Watch: Nine Approvals And Five Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Approvals
Interviews

IGBA’s Almeida On Patent Quality, Single Data Package Globally For Off-Patent Drugs

IGBA's secretary general, in an interview with Scrip, bolsters the case for enabling single global development of off-patent medicines and the acceptance of foreign comparators in bioequivalence studies as complex and niche therapeutics increasingly dot pharma’s pipeline. The global off-patent industry association, she maintained, is also “paying attention” to patent quality in various regions.

Policy Regulation

Beacon Eye Gene Therapy Efforts Buoyed By Cash Boost

In a major boost for the UK biotech sector, an impressive sum has been raised by Beacon Therapeutics to support its R&D activities in ophthalmic gene therapies.

Ophthalmic Financing

Sutro Works Toward A Better Ovarian Cancer ADC

Sutro Biopharma CEO Bill Newell spoke with Scrip about the company’s novel platform, its goal of improving folate receptor alpha-driven ovarian cancer and its business development strategy.

BIO Cancer

Amgen’s Ian Thompson On Payer Shifts, Obesity Opportunity And The Future Of Blockbusters

Scrip spoke with Amgen’s senior VP of US business operations about the impact of drug pricing and reimbursement pressures coming from government policy changes and commercial payers.

Launches Pricing Strategies
See All
Graphics

Deal Volume Up, Value Down During The First Half

Without a mega-merger like 2023’s Pfizer/Seagan takeout, M&A deals grew smaller during the first half of 2024, while volume rose. In alliance deals, H1 2024 activity somewhat mirrored activity from H1 2023.

Deals M & A

Top 10 Drugs Q1 2024: Keytruda Reigns, Trikafta Debuts

Keytruda enjoyed its fifth consecutive quarter as the world’s top-selling drug in the first three months of 2024. As Comirnaty and Spikevax fell out of the list, Vertex’s cystic fibrosis pill Trikafta/Kaftrio became one of the top 10 best-selling drugs for the first time.

Sales & Earnings Commercial

Titans Of Pharma: J&J Back On Top For CEO Remuneration

J&J topped the league table for CEO pay in 2023, a position it has held for three of the four past years. Meanwhile, the two companies that arguably generated the most buzz in 2023 neatly depict the stark contrast between the US and Europe when it comes to executive remuneration.

Leadership Companies

New Promise, Looming Competition For DMD In China

With several new drugs progressing for the estimated 70,000 patients in China with DMD, a recent setback for Nippon Shinyaku's contender and progress for Chinese gene therapy developers are adding both uncertainty and likely competition in an untapped market with pressing medical need.

China Clinical Trials
See All
Recent Stories

Immutep LAG-3 Inhibitor May Have Path Forward

After missing statistical significance in PD-L1+ head-and-neck cancer, Immutep presents data showing eftilagimod with Keytruda can offer efficacy in PD-L1-negative patients.

Clinical Trials ImmunoOncology

Pipeline Watch: 11 Approvals And Two Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Approvals

Novo Nordisk’s Weekly Insulin Trips Just Before Finish Line

The drug maker said the US FDA issued a complete response letter for insulin icodec that included requests related to manufacturing process and the type 1 diabetes indication.

Complete Response Letters Metabolic Disorders

Pfizer Advancing Once-Daily Danuglipron For Obesity

A modified-release formulation of the oral GLP-1 has been selected for development, Pfizer said. Dose-optimization studies will begin in the second half of the year.

Metabolic Disorders Research & Development

Executives On The Move: Three New CEOs Among This Week's Changes

Recent moves in the industry include C-suite shuffle at Armis Biopharma, plus Voyager Therapeutics acquires chief financial officer from Vor Biopharma.

Leadership Executive Changes

IPOs Collapse In The Second Quarter

Biotechs have had a difficult time raising cash through flotations over the past quarter, with one stepping away altogether.

Financing Business Strategies

Ipsen Doubles Up In ADC Arena With Foreseen Alliance

Deal Snapshot: Ipsen has entered into a global licensing agreement with Foreseen Biotechnology potentially worth up to $1.03bn, its second antibody-drug conjugate tie-up this year, a few months after unveiling a partnership with Sutro.

Deals Cancer

HUTCHMED Switches Clinical Strategy To Rely On Partnerships For Late-Stage Assets In US

Having initiated China-only Phase III trials with three oncology and autoimmune drug candidates, HUTCHMED is looking for partnerships to take the molecules to the clinic in the US.

China Clinical Trials

FTC’s PBM Investigation Could Yield Litigation Over Insulin Contracting

The US Federal Trade Commission’s focus on potential anti-competitive behavior by pharmacy benefit managers picks up steam as Chair Lina Khan approaches the end of her term.

Reimbursement Pricing Debate

Deal Volume Up, Value Down During The First Half

Without a mega-merger like 2023’s Pfizer/Seagan takeout, M&A deals grew smaller during the first half of 2024, while volume rose. In alliance deals, H1 2024 activity somewhat mirrored activity from H1 2023.

Deals M & A

Flagship Plans To Distribute New Fund To About Two Dozen Companies

The venture capital firm announced a $3.6bn raise for Fund VIII and side funds, which it plans to invest across human health, AI and sustainability-focused companies.

Financing StartUps and SMEs

Amylyx Steps Outside Neurodegenerative Disease With New Late-Stage Asset

The company outlined plans to develop newly acquired GLP-1 antagonist avexitide. CEOs Joshua Cohen and Justin Klee talked to Scrip about the strategy.

Deals Research & Development
UsernamePublicRestriction

Register